Citing concerns about mRNA technology, the Trump administration has pulled funding for a vaccine, even though Moderna says it ...

Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all ...

Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event ...

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Universal immunisation with nirsevimab significantly reduces hospitalizations and paediatric intensive care admissions for ...

The new three-illness dashboard includes a history of outbreaks for any or all of the three respiratory illnesses. It ...

A statewide immunization program for infants against respiratory syncytial virus (RSV), which began in 2024, has already ...